Yu Dechao

Yu Dechao (Chinese: 俞德超, born February 4, 1964) also known as Michael Yu,[1] is the founder and CEO of Innovent Biologics.[2] He received Doctor of philosophy degree in Genetics from the Chinese Academy of Sciences[3] and completed post-doctoral training in pharmaceutical chemistry at the UCSF.[4] As an inventor and owner of more than 60 patents (including 38 U.S. patents),[4] Yu established Innovent Biologics in 2011.[5] He is a professor and doctoral supervisor of Sichuan University, a visiting professor of Zhejiang University and an adjunct professor at Suzhou University,[6] the chairman of the board of the Chinese Antibody Society.[7]

Biography

Yu was a co-founder, President and CEO of Chengdu Kanghong Biotech from 2006 to 2010, and the vice president of Research and Development at Applied Genetic Technologies Corporation (NASDAQ: AGTC) and Calydon, Inc.,[8] the latter was acquired by Cell Genesys, Inc. in 2001, where he worked for three years following the acquisition.[9] In 2011, Yu founded Innovent Biologics, and it became listed on the Main Board of the HKEX with the stock code: 01801.HK. on October 31, 2018.[10]

Achievements in biomedicine

Yu invented and developed three "Class I" drugs in China.[11] He invented Conbercept (brand name: Langmu, a drug for ocular diseases and oncology), which is China's first monoclonal antibody product;[12] Oncorine (an oncology product),[13] which is the world's first oncolytic virus product;[14] Tyvyt (generic name: sintilimab), which is the domestically developed PD-1 antibody jointly developed by Innovent Biologics and Eli Lilly and Company,[15] and the key clinical results of Tyvyt in patients with r/r cHL have been published by the Lancet Haematology.[16] And Tyvyt has been officially approved by the National Medical Products Administration of China[17] for marketing in China for relapsed or refractory classical Hodgkin’s lymphoma (r/r cHL) as the first approved indication.[18]

Awards and recognition

Yu Dechao was selected as "Most Influential Overseas Returnee in Life Sciences" in 2013; one of the "Top Ten Figure of Innovation in China" in 2014; "E&Y Entrepreneur of the Year in China" in 2015; "Distinguished Entrepreneur of Jiangsu Province" in 2016;[7] national "Person of the Year in Innovation for Science and Technology in 2016" in January 2017;[7] awarded as "The Seventh National Overseas Returnee Contributions Awards" in 2018.[9]

gollark: KikiyoumonsterIamblockingyouforeveeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeer
gollark: Mostly xenowyrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrms though.
gollark: I quite like coppeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeers
gollark: All hail the __**FISH OF SUNS**__.
gollark: In real life I actually have about six chickens.

References
  1. Macular Degeneration: New Insights for the Healthcare Professional: 2013 Edition: ScholarlyBrief. ScholarlyEditions. 22 July 2013. pp. 22–. ISBN 978-1-4816-5391-6.
  2. "Capital Group Eyes Pre-IPO Stake in China Biotech Unicorn". Bloomberg News. Retrieved 15 January 2018.
  3. "Michael Yu:High Quality Drugs Should be Affordable to Ordinary People". Chinese Academy of Sciences. Retrieved 1 December 2015.
  4. "Recruitment program a magnet for talent". China Daily. Apr 20, 2017.
  5. "Capital Group eyeing stake in China biotech unicorn". The Star (Malaysia). Retrieved 17 January 2018.
  6. "关于公布江苏省第五批产业教授（兼职）" (PDF). Southeast University. Retrieved Dec 28, 2017.
  7. "集贤大讲坛：开发出中国老百姓用得起的高质量生物药". Zhejiang A & F University. Retrieved Apr 13, 2017.
  8. Pablo Hernáiz Driever; Samuel D. Rabkin (1 January 2001). Replication-competent Viruses for Cancer Therapy. Karger Medical and Scientific Publishers. pp. 56–. ISBN 978-3-8055-7248-4.
  9. "directors and senior management" (PDF). etnet.com. Retrieved 18 October 2018.
  10. "UPDATE 3-China's Innovent Biologics surges in Hong Kong debut". Reuters. Retrieved 30 October 2018.
  11. "加快迈向新药研发大国". People's Daily. Retrieved Feb 20, 2019.
  12. "Yu Dechao: Developer of Chinese Biopharmaceuticals". China Today. Retrieved Oct 10, 2016.
  13. Shuren Zhang (30 May 2016). Progress in Cancer Immunotherapy. Springer. pp. 244–. ISBN 978-94-017-7555-7.
  14. Liang, M. (2018). "Oncorine, the World First Oncolytic Virus Medicine and its Update in China". Current Cancer Drug Targets. 18 (2): 171–176. doi:10.2174/1568009618666171129221503. PMID 29189159.
  15. "China Approves Tyvyt For Hodgkin's Lymphoma". Asian Scientist Magazine. Apr 20, 2017. Retrieved January 9, 2019.
  16. Ansell, S. M. (2019). "Sintilimab: Another effective immune checkpoint inhibitor in classical Hodgkin lymphoma". The Lancet. Haematology. 6 (1): e2–e3. doi:10.1016/S2352-3026(18)30210-2. PMID 30612711.
  17. "治疗霍奇金淋巴瘤的PD-1抗体药物信迪利单抗注射液获批上市". nmpa.gov.cn. Retrieved 28 December 2018.
  18. Hoy, S. M. (2019). "Sintilimab: First Global Approval". Drugs. 79 (3): 341–346. doi:10.1007/s40265-019-1066-z. PMID 30742278.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.